Wellcome Leap logo
In Utero

In Utero — Execution

Funds United Kingdom stillbirth-reduction initiatives with prenatal intervention and translational implementation support.

In Utero is a $50 million Wellcome Leap program directed by Sarah Stock, MD, PhD, Professor and Consultant in Maternal and Fetal Health with expertise in stillbirth and preterm birth. The program's central goal is to cut global stillbirth rates in half by creating scalable, non-invasive methods to measure, model, and predict gestational development in utero. The urgency of the problem is quantifie

Scalable non-invasive measurement and prediction of gestational development in utero, with the goal of cutting the global stillbirth rate in half by improving early identification of at-risk pregnancies.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.One-off
Next deadlineiThe next date applications are due. Rolling means you can apply any time.
Decision timeiTypical time from the deadline to the funder's decision.
Project durationiHow long the funded work is expected to run.
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Cooperative agreement
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.$50M

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Last verified: 22 Jul 2026Source: wellcomeleap.org